Applied Therapeutics, Inc.: Nasdaq/NYSE listing notice — Applied Therapeutics gets Nasdaq deficiency notice as equity falls below $10M minimum

Applied Therapeutics, Inc.

Stockholders' equity was $9.6M as of Sep 30, 2022, below Nasdaq's $10M continued listing requirement.
Company has until Dec 30, 2022 to submit a compliance plan to regain compliance.
If plan accepted, Nasdaq may grant until May 14, 2023 to evidence compliance.
No decisions on response have been made; continued listing not assured.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Applied Therapeutics, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5450(b)(1)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 5450(b)(1)(A)

Exact text from the filing

November 15, 2022, Applied Therapeutics, Inc. (the “Company”) received written notification (the “Notice”) from the Nasdaq Stock Market (“Nasdaq”) that, the Company’s stockholders’ equity as reported in its Quarterly Report on Form 10-Q for the period ended September 30, 2022 (the “Form 10-Q”) does not satisfy the continued listing requirement under Nasdaq Listing Rule 5450(b)(1)(A) for the Nasdaq Global Market, which requires that a listed company’s stockholders’ equity be at least $10.0 million (the “Stockholders’ Equity Requirement”). As reported in its Form 10-Q, the Company’s stockholders

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001104659-22-120350

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.